Hemophagocytic lymphohistiocytosis (HLH) is a severe and life-threatening syndrome characterized by overwhelming inflammation that often leads to multiorgan…
#EpsteinBarrVirus hijacks #Bcell #Metabolism to establish persistent infection and drive #Pathogenesis | Open Access Review by Bojana Müller et al breaking at…
ASH Annual Meeting Abstracts Latest Announcements Late-Breaking Abstracts Now Available Late-breaking abstracts feature substantive, novel, and groundbreaking data that were not available by the general abstract submission deadline and would otherwise not be presented at the ASH annual meeting. View the 2024 Late-Breaking Abstracts 2024 ASH Annual Meeting Abstracts Abstracts for the 2024 ASH Annual Meeting and Exposition, including late-breaking abstracts, are now available. A record-breaking number of abstracts were submitted and more than 7,950 were accepted. View the accepted abstracts representing the most cutting-edge science in hematology. View the 2024 Abstracts About ASH Annual Meeting Abstracts Abstracts submitted for oral and poster presentation at the ASH annual meeting represent important, novel research in the field and are considered the best of the thousands of abstracts submitted. Typically, more than 7,000 scientific abstracts are submitted each year, and more than 5,000 abstracts are accepted for oral and poster presentations through an extensive peer review process. Abstract categories are reviewed and updated annually to respond to trends and cover new areas. This year, updates include The renumbering of categories (particularly those in the 600 and 900 groupings) The discontinuation of two categories (731. Autologous Transplantation, and 705. Cellular Immunotherapies: Commercial and Late Stage) The addition of several new categories (909. Education, Communication, and Workforce, 628. Aggressive Lymphomas: Cellular Therapies, and 655. Multiple Myeloma: Cellular therapies) The splitting of several categories (including several in thrombosis and homeostasis, clinical lymphomas, and health services, quality improvement and outcomes research). View the full list of abstract categories. The Plenary Scientific Session, which includes the top six abstracts as selected by the Program Committee, is traditionally a highlight of the annual meeting program. View the 2024 Abstracts Key Dates and Deadlines Abstract submission site opens May 30, 2024 Abstract submission deadline August 1, 2024, 11:59 p.m. Pacific time Abstract withdrawal deadline September 18, 2024 Call for late-breaking abstract submissions October 16-28, 2024 Abstracts available online November 5, 2024, 9:00 a.m. Eastern time Abstract poster presentation materials due November 12, 2024 Late-breaking abstracts available online November 25, 2024, 9:00 a.m. Eastern time Related Content Call for Late-Breaking Abstracts Late-breaking abstract submissions for the 2024 ASH Annual Meeting and Exposition are open from October 16, 2024, through October 28, 2024, at 11:59 p.m. Pacific time. No submissions will be accepted after this deadline. Learn More > Call for Abstracts Abstract submissions for the 2024 ASH Annual Meeting and Exposition are open from May 30, 2024, through August 1, 2024, at 11:59 p.m. Pacific time. No submissions will be accepted after this deadline. Learn More > Poster Walks Poster Walks highlight abstracts submitted to the annual meeting that showcase emerging science in hematology. Learn More > Copyright and Reuse Policy Material presented at the annual meeting is subject to copyright or other reuse restrictions. Learn More > Abstract Achievement Awards Merit-based awards are provided to trainees with high-scoring annual meeting abstracts of which they are the first or senior author and presenter. Learn More > 66th ASH Annual Meeting and exposition Registration for ASH members, non-members, groups, exhibitors, and media is now open! View Additional Information Explore the Annual Meeting Schedule and Program Hotel and Travel Information Abstracts Meeting and Presenter Resources CME and MOC Information Code of Conduct
Using video microscopy in the living mouse lung, UC San Francisco scientists have revealed that the lungs play a previously unrecognized role in blood production.
Today’s EHA #ThinkingThursday focuses on available therapies for #Hemophilia B (also known as Christmas disease). Can you fill in A, B and C? Share your…
Long-term survival rates for patients with leukemia after hematopoietic cell transplantation (HCT) are encouraging but personalized transplant strategies remain important to improve outcomes.
Acute lymphoblastic leukaemia (ALL) is a haematological malignancy characterized by the uncontrolled proliferation of immature lymphoid cells. Over past decades, significant progress has been made in understanding the biology of ALL, resulting in remarkable improvements in its diagnosis, treatment and monitoring. Since the advent of chemotherapy, ALL has been the platform to test for innovative approaches applicable to cancer in general. For example, the advent of omics medicine has led to a deeper understanding of the molecular and genetic features that underpin ALL. Innovations in genomic profiling techniques have identified specific genetic alterations and mutations that drive ALL, inspiring new therapies. Targeted agents, such as tyrosine kinase inhibitors and immunotherapies, have shown promising results in subgroups of patients while minimizing adverse effects. Furthermore, the development of chimeric antigen receptor T cell therapy represents a breakthrough in ALL treatment, resulting in remarkable responses and potential long-term remissions. Advances are not limited to treatment modalities alone. Measurable residual disease monitoring and ex vivo drug response profiling screening have provided earlier detection of disease relapse and identification of exceptional responders, enabling clinicians to adjust treatment strategies for individual patients. Decades of supportive and prophylactic care have improved the management of treatment-related complications, enhancing the quality of life for patients with ALL. Acute lymphoblastic leukaemia (ALL) is a haematological malignancy characterized by the uncontrolled proliferation of immature lymphoid cells. In this Primer, Pagliaro et al. discuss the epidemiology, mechanisms, diagnosis and treatments of ALL.
C’est l’histoire d’un garçon de 5 ans qui présente de nombreuses hémorragies survenant le plus souvent quand il joue. Le petit patient a été transfusé à de nombreuses reprises, chaque transfusion entrainant l’arrêt du saignement. Son cas a été publié le 27 décembre 1952 dans le numéro de Noël du British Medical Journal (BMJ). Il …
Follicular lymphoma (FL) is an indolent yet incurable germinal center B-cell lymphoma retaining a characteristic follicular architecture. FL tumor B cells are h
Over the past decades, the progressive identification of chromosomal abnormalities and gene mutations has transformed acute myeloid leukemia (AML) fro…
0:00 Introduction 0:45 What Is Systems-Based Hematology? 1:30 Gaps in the Field 2:05 ASH Study and Results 6:40 Designing a Curriculum 8:56 How This Affects Patients
In this episode, Dr. Richard Godby shares more about his team’s ASH presentation on creating a standardized curriculum for systems-based hematology, including gaps, challenges, and future directions in this emerging discipline.
Learn about: - What systems-based hematology means - His team’s study interviewing experts in the field - Themes that the interviews revealed - How these results can be used to inform the development of educational resources and training programs for systems-based hematology - Next steps for the research - How this research might affect patient care - And more!
📝Publié ! 6 ans après le début de ce projet qui s’inscrit dans la continuité de la recherche de l’équipe du Pr Eric Solary à Gustave Roussy, les résultats de…
The bone marrow microenvironment is a critical regulator of haematopoietic stem cell self-renewal and fate1. Although it is appreciated that ageing, chronic inflammation and other insults compromise bone marrow function and thereby negatively affect haematopoiesis2, it is not known whether different bone compartments exhibit distinct microenvironmental properties and functional resilience. Here we use imaging, pharmacological approaches and mouse genetics to uncover specialized properties of bone marrow in adult and ageing skull. Specifically, we show that the skull bone marrow undergoes lifelong expansion involving vascular growth, which results in an increasing contribution to total haematopoietic output. Furthermore, skull is largely protected against major hallmarks of ageing, including upregulation of pro-inflammatory cytokines, adipogenesis and loss of vascular integrity. Conspicuous rapid and dynamic changes to the skull vasculature and bone marrow are induced by physiological alterations, namely pregnancy, but also pathological challenges, such as stroke and experimental chronic myeloid leukaemia. These responses are highly distinct from femur, the most extensively studied bone marrow compartment. We propose that skull harbours a protected and dynamically expanding bone marrow microenvironment, which is relevant for experimental studies and, potentially, for clinical treatments in humans. Skull bone marrow expands during adult life, exhibits lifelong vascular growth and increases its haematopoietic potential during ageing.
Autoimmune haemolytic anaemias are a group of anaemias mediated by the presence of autoantibodies targeting antigens expressed on red blood cells, leading to their destruction. In this Primer, Michel and colleagues summarize the epidemiology, pathophysiology, diagnosis and management of this...
Tissue inflammation is a hallmark of tumour microenvironments. In the bone marrow, tumour-associated inflammation impacts normal niches for haematopoietic progenitor cells and mature immune cells and supports the outgrowth and survival of malignant cells residing in these niche compartments. This Review provides an overview of our current understanding of inflammatory changes in the bone marrow microenvironment of myeloid and lymphoid malignancies, using acute myeloid leukaemia and multiple myeloma as examples and highlights unique and shared features of inflammation in niches for progenitor cells and plasma cells. Importantly, inflammation exerts profoundly different effects on normal bone marrow niches in these malignancies, and we provide context for possible drivers of these divergent effects. We explore the role of tumour cells in inflammatory changes, as well as the role of cellular constituents of normal bone marrow niches, including myeloid cells and stromal cells. Integrating knowledge of disease-specific dynamics of malignancy-associated bone marrow inflammation will provide a necessary framework for future targeting of these processes to improve patient outcome. Haematological malignancies are associated with inflammation in the bone marrow. In this Review, the authors discuss how tumour-associated inflammation affects the normal functions of the bone marrow and supports the outgrowth and survival of malignant cells. Moreover, they describe how the inflammatory changes in the bone marrow differ in myeloid and lymphoid malignancies.
A anemia no idoso tem uma elevada prevalência sendo de 26% em indivíduos com +75 anos, onde neste grupo etário a prevalência da deficiência de ferro é de 37%. No idoso 1/3 dos casos de anemia são devidos a uma alimentação deficiente em elementos nutricionais essenciais e 1/3 a doença crónica, nomeadamente gastrointestinal, cardíaca ou renal.
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
Your new post is loading...
Scoop.it!
Hospital choices did not allow to pursue the efforts locally...
but to stay informed and allow others to surf the information wave....
Much information is available in the cloud, focusing on immunophenotyping of leukemias, and also on other haematology topics.
Blood cells being also immunocompetent cells, other topics curated should be of interest
http://www.scoop.it/t/immunology
http://www.scoop.it/t/from-flow-cytometry-to-cytomics
http://www.scoop.it/t/immunology-and-biotherapies